Page last updated: 2024-08-05 12:00:05
phenylindole
null
ChEBI ID: 48559
Members (12)
Member | Definition | Role |
1-(3,5-dimethyl-1-pyrazolyl)-3-[2-(4-methoxyphenyl)-1-indolyl]-2-propanol | | 1-(3,5-dimethyl-1-pyrazolyl)-3-[2-(4-methoxyphenyl)-1-indolyl]-2-propanol |
2-(1-methyl-2-phenyl-3-indolyl)ethanol | | 2-(1-methyl-2-phenyl-3-indolyl)ethanol |
2-(2-methoxyphenyl)-1H-indole | | 2-(2-methoxyphenyl)-1H-indole |
2-oxo-N-[2-[(2-phenyl-1H-indol-3-yl)thio]ethyl]-1-benzopyran-3-carboxamide | | 2-oxo-N-[2-[(2-phenyl-1H-indol-3-yl)thio]ethyl]-1-benzopyran-3-carboxamide |
2-phenylindole | | 2-phenyl-1H-indole |
2-phenylmelatonin | | N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide |
bazedoxifene | | bazedoxifene |
l803087 | A fluoroindole that is 1H-indole substituted by phenyl, 4-{[(2S)-5-carbamimidamido-1-methoxy-1-oxopentan-2-yl]amino}-4-oxobutyl, fluoro and fluoro groups at positions 2, 3, 5 and 7, respectively. It is a selective nonpeptidic agonist of the somatostatin subtype-4 (SST4) receptor with Ki of 0.7 nM. | L-803087 |
N-[2-[[2-(4-methylphenyl)-1H-indol-3-yl]thio]ethyl]-2-oxo-1-benzopyran-3-carboxamide | | N-[2-[[2-(4-methylphenyl)-1H-indol-3-yl]thio]ethyl]-2-oxo-1-benzopyran-3-carboxamide |
n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide | | 2-[2-(4-fluorophenyl)-1H-indol-3-yl]-N,N-dihexylacetamide |
sertindole | A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group. | sertindole |
zindoxifene | | Zindoxifene |
Research
Studies (707)
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
pre-1990 | 12 (1.70) | 18.7374 |
1990's | 107 (15.13) | 18.2507 |
2000's | 169 (23.90) | 29.6817 |
2010's | 351 (49.65) | 24.3611 |
2020's | 68 (9.62) | 2.80 |
Study Types
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
Trials | 103 (13.31%) | 5.53% |
Reviews | 150 (19.38%) | 6.00% |
Case Studies | 25 (3.23%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 496 (64.08%) | 84.16% |